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prognostic Impact of Longitudinal 
Monitoring of Radiomic Features in 
patients with Advanced Non-small 
Cell Lung Cancer
so Hyeon Bak  1,3, Hyunjin park4,5, Insuk sohn6, Seung Hak Lee7, Myung-Ju Ahn8 & 
Ho Yun Lee1,2
tumor growth dynamics vary substantially in non-small cell lung cancer (NsCLC). We aimed to develop 
biomarkers reflecting longitudinal change of radiomic features in NSCLC and evaluate their prognostic 
power. Fifty-three patients with advanced NSCLC were included. Three primary variables reflecting 
patterns of longitudinal change were extracted: area under the curve of longitudinal change (AUC1), 
beta value reflecting slope over time, and AUC2, a value obtained by considering the slope and area over 
the longitudinal change of features. We constructed models for predicting survival with multivariate cox 
regression, and identified the performance of these models. AUC2 exhibited an excellent correlation 
between patterns of longitudinal volume change and a significant difference in overall survival time. 
Multivariate regression analysis based on cut-off values of radiomic features extracted from baseline 
CT and AUC2 showed that kurtosis of positive pixel values and surface area from baseline CT, AUC2 of 
density, skewness of positive pixel values, and entropy at inner portion were associated with overall 
survival. For the prediction model, the areas under the receiver operating characteristic curve (AUROC) 
were 0.948 and 0.862 at 1 and 3 years of follow-up, respectively. Longitudinal change of radiomic tumor 
features may serve as prognostic biomarkers in patients with advanced NsCLC.
Accurate radiological assessment for predicting therapeutic responses and clinical outcomes of non-small cell 
lung cancer (NSCLC) is important in clinical practice and drug development trials1. Cancers have uneven growth 
patterns, and even within single tumors specific areas may increase in size while other portions remain stable. 
Intratumoral heterogeneity reflecting heterogeneous biologic phenomenon can affect the rates and patterns of 
tumor growth2. With the development of targeted therapy and immunotherapy, tumor cells remain sensitive to 
targeted therapy beyond progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors 
(RECIST), while pseudoprogression occurs in patients undergoing immunotherapy due to infiltration of T cells 
and macrophages2,3. On the other hand, targeted therapy or immunotherapy is used continuously during tumor 
progression2,4, and as assessment of a therapeutic response is usually made between two time points, it may not 
capture the full spectrum of therapeutic response and could be insufficient in the era of personalized cancer 
treatment5.
Rapid reduction of tumor size is traditionally considered to be associated with better outcomes6. Recently, 
depth of response (DepoR), which indicates the maximum tumor shrinkage from baseline of a target lesion, has 
begun to be explored as a predictor of long-term treatment outcome7. However, recent studies suggest that DepoR 
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should not be used a surrogate of benefit in advanced epidermal growth factor receptor (EGFR)-mutant lung 
cancer8. Therefore, parameters such as continuous variables reflecting intratumoral heterogeneity and genomic 
alterations are needed to assess therapeutic response and clinical outcomes.
Quantitative imaging features may provide comprehensive information on tumor phenotypes and microenvi-
ronement9,10. Changes in quantitative features are considered a biomarker to accurately assess treatment response 
and clinical outcomes11. Recently, delta-radiomics, a time dependent metric comprised of quantitative features 
extracted from medical images acquired during the course of treatment has been considered as an emerging 
biomarker for assessing therapeutic responses and clinical outcomes12. We hypothesized that variables capable 
of reflecting various longitudinal changes in quantitative image features extracted from serial imaging over the 
course of treatment would be capable of superior prognosis prediction in NSCLC patients. The purpose of this 
study was to develop biomarkers based on longitudinal changes in quantitative radiomic features in patients with 
advanced NSCLC, and assess the prognostic power of these biomarkers.
Results
Demographics data. This study included 53 patients with stage IV NSCLC (19 men, 34 women; mean age, 
58.7 ± 10.6; range, 32–81 years). The histologic types of all patients were adenocarcinoma. Thirty-four patients 
(64.2%) were never smokers, 62.3% had exon 19 deletion, and 56.6% were treated with EGFR TKIs as a first-line 
of therapy. Forty (75.5%) patients had metastasis to the central nervous system (CNS), 27 of whom underwent 
local treatment. Among 53 patients, 27 (50.9%) died. The number of target lesions was 1 in 26 patients (49.0%), 2 
in 15 (28.3%), 3 in 10 (18.9%), and 4 in 2 (3.8%). The mean CT follow-up period from baseline to PD was 28 ± 15 
months. The characteristics of patients with advanced NSCLCs are presented in Table 1.
Development of radiologic variables reflecting longitudinal volume change. AUC1, AUC2, and 
beta value (Fig. 1) were calculated using the volume change of serial CTs from baseline to PD. The beta value 
exhibited a good correlation with the six patterns of volume change (r = 0.834, p < 0.000). Furthermore, AUC2 
reflecting under the area and slope during the follow-up period was well correlated with the six patterns of vol-
ume change (r = 0.848, p < 0.000) as well as beta value (r = 0.752, p < 0.000, Fig. 2). Therefore, AUC2 was consid-
ered to be a marker that reflects changes during the follow-up in patients with advanced NSCLC and was used for 
longitudinal analyses of the 23 quantitative CT features, including volume.
For the prediction of overall survival time, we calculated the cutoff of AUC1, AUC2, and beta value based on 
volume. When we selected cutoff values of 1.601 for AUC1, −0.738 for AUC2, and −0.176 for the beta value, the 
Characteristics No. of patients (%)
Age* 58.7 ± 10.6 (32–81)
Male:Female 19 (35.8):34 (64.2)
Smoking habits
   Nonsmoker 34 (64.2)
   Ex-smoker 11 (20.8)
   Current smoker 8 (15.1)
ECOG performance status
   0 2 (3.8)
   1 50 (94.3)
   2 1 (1.9)
M descriptor
   M1a 9 (17.0)
   M1b 44 (83)
Type of EGFR mutation
   Exon 19 deletion 33 (62.3)
   L858R 20 (37.7)
Line of EGFR TKIs
   First line 30 (56.6)
   Second line 23 (43.4)
EGFR TKIs
   Gefitinib 38 (71.7)
   Elrotinib 15 (28.3)
Overall survival
   Death 27 (50.9)
   Overall survival 26 (49.1)
Follow-up period (months)* 28 ± 15 (6–54)
Table 1. Demographics of 53 patients with advanced NSCLC. Note. __ ECOG, the Eastern Cooperative 
Oncology group; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKIs, tyrosine 
kinase inhibitors. *Data are mean ± standard deviation and data in parentheses are range.
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AUC2 and beta values showed significant differences in overall survival time (p = 0.035 for AUC2, and p = 0.029 
for beta value (Fig. 3). However, AUC1 did not exhibit a statistically significant difference with regards to overall 
survival (p = 0.086).
prognostic prediction model using longitudinal change of radiomic features. We extracted 
23 quantitative features including volume from baseline and follow-up CTs, and calculated the AUC2 of the 
quantitative CT features extracted from baseline to PD. Based on the cut-off values of quantitative features 
on baseline CT and AUC2 of quantitative values, all quantitative features were divided into two groups and 
univariate and multivariate cox regression analyses were performed to identify risk factors to predict overall 
survival time. Eighteen features were selected in the univariate analysis (supplementary Table 1). In our study, 
age, sex, the Eastern Cooperative Oncology group (ECOG) performance status, smoking status, type of EGFR 
mutation, CNS metastasis, and local treatment for CNS metastasis were not associated with overall survival 
time (p > 0.05). Six of the 18 features were selected by stepwise selection. Kurtosis of positive pixel values 
(p = < 0.000, HR, 7.992; 95% CI, 2.759–23.148) and surface area (p = 0.001, HR, 0.192; 95% CI, 0.075–0.493) 
on baseline CT, and AUC2 of density (p = < 0.000, HR, 0.067; 95% CI, 0.021–0.220), skewness of positive 
pixel values (p = 0.010, HR, 5.142; 95% CI, 1.490–17.747) and entropy at inner portion (p = 0.001, HR, 6.196; 
95% CI, 2.086–18.406) were associated with overall survival in multivariate cox analysis in patients with 
advanced NSCLC (Table 2).
The prediction model of overall survival was defined as a linear combination of the five selected features 
and their regression coefficients. For the prediction model, we constructed a time-dependent ROC curve from 
which the AUROC was calculated. At 1 and 3 years of follow-up, the AUROCs for overall survival were 0.948, 
and 0.862 (Fig. 4).
Figure 1. Schematic illustration of the values AUC1, beta and AUC2. AUC1 is defined as the area under 
the longitudinal change of values. The beta value is the slope calculated by linear regression over time, and 
represents the slope of the overall longitudinal change. AUC2 is value obtained by considering the slope and 
area of the longitudinal change. More specifically, subtraction is performed when the slope is negative, and 
addition is performed when the slope is positive.
Figure 2. Relationship between AUC2 and curve pattern of volume change (A) or beta value (B). (A) The six 
patterns of volume changes were follows: (1) reduction only but progressive disease due to nontarget lesions, 
(2) slow progression after rapid response, (3) rapid progression after rapid response, (4) slow progression after 
slight reduction, (5) rapid progression after slight reduction, and (6) sequential progression.
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Discussion
Radiomics studies of NSCLC are usually obtained from images at a single time point. Our studies extracted quan-
titative features from serial images obtained during the course of treatment in patients with advanced NSCLC. As 
a result of analyzing longitudinal changes in volume, we identified the variable AUC2 that reflects the slope and 
area of longitudinal change. Specifically, AUC2 of volume was helpful in predicting overall survival time. Based 
on this result, we also obtained the AUC2 for 23 quantitative features from serial CT images. Kurtosis of positive 
pixel values and surface area from baseline CT, AUC2 of density, skewness of positive pixel values, and entropy at 
inner portion were all associated with overall survival.
Figure 3. Comparison of Kaplan-Meier curve for overall survival of patients stratified by AUC1 (A), beta value 
(B) and AUC2 (C).
Selected features p Value HR 95% CI
AUC2
Density <0.000 0.067 0.021–0.220
Skewness of 
positive pixel 
value
0.010 5.142 1.490–17.747
Entropy at inner 0.001 6.196 2.086–18.406
Baseline
M descriptor 0.338 1.806 0.538–6.057
Kurtosis of 
positive pixel 
value
<0.000 7.992 2.759–23.148
Surface area 0.001 0.192 0.075–0.493
Table 2. Multivariate Cox regression analyses of overall survival using selected features based on AUC2 and 
baseline features. Note. __ CI, confidence interval; HR, hazard ratio.
Figure 4. Time-dependent receiver operating characteristic (ROC) curve for prediction model with six features 
predicting overall survival. The area under the ROC curve (AUROC) was 0.948 at 1 year (A), and 0.862 at 3 years (B).
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Imaging plays a central role in the evaluation of therapeutic response. Decrease in size, vascularity and metab-
olism, and cavitation within the tumor are well known typical responses to treatment13. However, although tumor 
size can increase with intralesional and/or perilesional hemorrhage, atypical responses consisting of decreased 
attenuation and metabolism of tumor may also be seen as the tumor becomes homogenous13.
As the use of targeted molecular therapy and immunotherapy increases in the era of personalized cancer 
treatment, morphological changes may be more important than changes in tumor size, and increases in the size 
of new lesions before dramatic shrinkage may also occur in relation to the immune response14. Patients treated 
with EGFR TKIs can experience a dramatic initial shrinkage of tumor followed by slow progression over several 
months, a finding that suggests the tumor cells remain sensitive to EGFR TKIs2,14. A recent study reported that 
88% of patients continued therapy beyond progression according RECIST15. Evaluating therapeutic response 
as a more continuous variable using DepoR has also begun to be explored, and DepoR is used not only in lung 
cancer, but in other cancers as well including colorectal cancer, breast cancer, and multiple myeloma16. A recent 
study showed that a greater DepoR is associated with better clinical outcome in NSCLC patients receiving an 
anaplastic lymphoma kinase (ALK) inhibitor or a programed cell death-1 (PD-1) inhibitor5. On the other hand, 
another study reported that DepoR does not correlate with clinical outcome8. Therefore, an approach based on a 
single marker is not sensitive to assessment of therapeutic response due to phenotypic and genomic heterogeneity 
between lesions, even within an individual tumor17,18.
Radiomics is defined as quantitative mapping that converts medial images to automatically extracted quan-
titative features and provides information related to the comprehensive pathophysiology of a tumor12,19. The use 
of radiomics in lung cancer studies is focused on patient outcomes, nodule discrimination, and assessment of 
genetic mutations20. Whereas most radiomics studies are performed using pretreatment images, the concept of 
delta-radiomics was introduced to analyze quantitative features from images acquired over the course of treat-
ment by adding a time component to existing radiomic features12. Delta-radiomics may be used as indicator 
to predict response in colorectal liver metastasis, metastatic lung cancer, esophageal cancer, and NSCLC21–25. 
Previous studies have shown that tumor volume is a key predictor reflecting histological tumor aggressiveness 
and poor prognosis in patients with NSCLC26,27. Volumetric measurements that are able to capture tumor changes 
along the z-axis may be useful for more sensitively and specifically monitoring disease change over time28–30. 
Therefore, in our study, we examined longitudinal changes in tumor volume. We measured additional variables 
reflecting longitudinal change, and from those variable calculated corresponding AUC1 values reflecting the area 
of volume change, beta value reflecting slope of change, and AUC2 reflecting area and slope. AUC2 exhibited a 
good correlation with curve pattern (r = 0.848, p < 0.000) and beta value (r = 0.752, p < 0.000), whereas the AUC2 
of tumor volume was associated with overall survival (p = 0.035). Thus, AUC2 may be a new biomarker that 
reflects longitudinal changes in lesions and predicts overall survival time and treatment response.
Size and volume of a tumor do not reflect changes in tumor heterogeneity and genetic profiles23. However, 
radiomic features can provide more comprehensive information about tumor makeup. A study showed that a 
novel set of quantitative image features, based on heterogeneities of tumor physiology, was helpful for early pre-
diction of treatment outcome31. Therefore, we obtained AUC2 values for 23 quantitative features, including vol-
ume, that were previously reported to be associated with lung cancer32–37. We examined the association between 
these 23 pretreatment quantitative features and 23 AUC2s obtained from serial images with overall survival. 
The result of our study showed that kurtosis of positive pixel values (p = <0.000) and surface area (p = 0.001) on 
baseline CT, and AUC2 of density (p < 0.000), skewness of positive pixel values (p = 0.010), and entropy at inner 
portion (p = 0.001) were all associated with overall survival according to a multivariate analysis in patients with 
advanced NSCLC.
Targeted therapies developed in recent years can cause tumor necrosis, hemorrhage, or cavitation, and radi-
omic features based on histograms may be useful for predicting these pathologic response27. In patients with 
a gastrointestinal stromal tumor, treatment with imatinib results in a decrease in tumor density such that the 
appearance becomes homogenous on CT, even though the decrease in tumor size is minimal at an early posttreat-
ment time point38. In our study with advanced NSCLC, density change was associated with increased survival, 
and it has been suggested that increased homogeneity during the course of treatment is related with therapeu-
tic response and prognosis. Two studies reported that a reduction of entropy reflecting tumor heterogeneity as 
a parameter to evaluate treatment response in colorectal liver metastases and renal cell carcinoma24,25. In our 
study, we found that the AUC2 of entropy at inner portion was successful for predicting overall survival time 
in advanced NSCLC. In addition, the AUC2 of the skewness of positive pixel value was found to be predictor of 
overall survival. Skewness is the distribution pattern of CT attenuation values, and decreased skewness reflects 
decreased enhancement due to decreased neovascularization during the course of treatment34. Therefore, based 
on our results, changes in tumor heterogeneity were related to overall survival time.
Morphological features reflecting the physical characteristics of tumors are important features related to 
aggressiveness18,39. Irregularity of tumor shape reflecting non-uniform growth of tumors is associated with worse 
overall survival in patients with lung squamous cell carcinoma and lung adenocarcinoma32,40. In our study, sur-
face area on baseline CT was associated with overall survival time in patients with advanced lung cancer, and 
morphologic features of tumor were considered important predictors related to clinical outcomes.
This study had several limitations. First, the sample size of the present study was small, and our study included 
patients in various treatment course. However, inclusion of patients with various treatment course may provide a 
better, more comprehensive assessment of overall survival of patients with advanced lung cancer. A second limi-
tation of this study was that we did not externally validate our results. Therefore, subsequent studies with a large 
population and external validation are necessary for validation of our results. Third, tumor volume and radiomic 
features are susceptible to respiration due to collapse and stretching of the tumor and peritumoral lung paren-
chyma41,42. In order to minimize this effect, we excluded patients who had severe respiratory difference in chest 
CTs or had concurrent disease such as effusion. Fourth, we selected target lesions according to RECIST (version 
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1.1) criteria. However, current RECIST guidelines may not reflect the overall body tumor load in patients with 
metastatic cancer. In addition, selection of target lesions is crucial and the result of response classification could 
be changed by target lesion selection43,44. The final limitation of our study was that the ROIs were drawn manually 
by a single operator. As tumor segmentation is the most critical process, and it is well recognized that interopera-
tor variability of manual segmentation of lesion is high9.
Conclusion
Our study showed that AUC2, a value that reflects the slope and area of longitudinal change calculated from radi-
omic measurements, is associated with patient survival. Quantitative analysis is a noninvasive technique reflect-
ing comprehensive information such as tumor heterogeneity and genetic profile. In addition, changes in these 
radiomics features during serial follow-up may provide comprehensive information about response to treatment 
and prognosis. Therefore, the results of our study suggest that longitudinal change of radiomic tumor features 
may be useful as prognostic biomarkers in patients with advanced NSCLC.
Materials and Methods
study population. From January 2012 to October 2014, we recruited 80 patients with advanced or recurrent 
NSCLC with confirmed EGFR mutation treated with a tyrosine kinase inhibitor (TKI) and who had been eval-
uated for therapeutic response on computed tomography (CT) until PD on treatment. Treatment response was 
assessed according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). There was no change 
in TKI type during the course of treatment. Twenty-seven patients were excluded from our study based on the 
following exclusion criteria: (1) patients who underwent surgical resection (n = 9), (2) patients without stage IV 
disease (n = 1), and (3) patient without available serial CTs (n = 17). Thus, a total of 53 patients with advanced 
NSCLC were included in this retrospective study. The study was approved by the Institutional Review Board 
(IRB) of Samsung Medical Center (IRB number 2015-10-108), and the requirement for informed consent was 
waived.
Image acquisition. All helical CT images were obtained with a 64 detector-row (LightSpeed VCT; GE 
Healthcare, Waukesha, WI, USA) CT scanner using the following parameters: detector collimation, 1.25 or 
0.625 mm; field of view, 36 cm; 125 mA; 120 kVp; beam width, 10–20 mm; beam pitch, 1.375–1.5; section thick-
ness 2.5 mm; and matrix, 512 × 512 mm. All patients underwent chest CT at full inspiration through breath hold 
to minimize the effect of the tumor motion due to breathing. Chest CT scanning was obtained 90 seconds after the 
administration of contrast material. A total of 1.5 mL/kg (body weight) Iomeron 300 (Iomeprol, 300 mg iodine/mL; 
Bracco; Milan, Italy) was injected at an infusion rate of 3 mL/s using a power injector (MCT Plus; Medrad; 
Pittsburgh, PA, USA). Image data were reconstructed with a soft-tissue algorithm for mediastinal window ranges 
and a bone algorithm for lung window images. Both mediastinal (width, 300 Hounsfield units [HU]; level, 20 
HU) and lung (width, 1500 HU; level −700 HU) window images were displayed for tumor assessment. Chest CT 
images were obtained every two cycles (8 weeks) during the course of treatment.
Image analysis. Based on RECIST criteria, up to 5 target lesions on baseline and follow-up chest CT were 
segmented by drawing a region of interest (ROI) that traced the edge of the lesion on all axial images until the 
entire lesion was covered. Nontarget lesions were ignored for the analysis of tumor change. Quantitative features 
were computed over an ROI drawn by a radiologist using MRIcro (version 1.40, Chris Rorden, University of 
Nottingham, Great Britain). From the baseline to the PD time point, a total of 161 quantitative CT features from 
each serial CTs were computed using a MATLAB function designed in house (Mathworks Inc., MA, USA). Of 
the 161 quantitative CT features, 23 features with a known association with lung cancer were selected and used 
for our analysis (Supplementary Table S2). In all available CTs, volume referred to the measurement of the sum of 
the target lesions and other quantitative features were measured from the volume weighted average of the target 
lesions.
We extracted three variables reflecting various patterns of longitudinal change of radiomic features including 
volume, namely, area under the curve (AUC1), beta value, and AUC2 (Fig. 1). AUC1 is a variable that represents 
the area of the longitudinal change of a quantitative feature. The beta value refers to the slope calculated by linear 
regression over time, that is, overall slope of change during follow-up. Third, AUC2 is a value obtained by con-
sidering the slope and area of the longitudinal changes of quantitative features. We investigated the relationship 
between the three variables obtained from the volume of target lesions and six patterns visually divided based 
on the patterns of longitudinal volume change. The six patterns reflecting longitudinal change of volumes were 
as follows: 1) reduction only but PD due to non-target lesions, 2) slow progression after rapid response, 3) rapid 
progression after rapid response, 4) slow progression after slight reduction, 5) rapid progression after slight reduc-
tion, 6) and sequential progression.
statistical analysis. Analyses were performed using SAS version 9.4 (SAS institute, Cary, NC) and R 3.3.1 
(Vienna, Austria; http://www.R-project.org/). A p value less than 0.05 was considered statistically significant.
Correlation between novel markers and pattern of longitudinal volume change. AUC1, beta value and AUC2 were 
obtained by the following methods. The regression coefficient of radiomic feature’s value over time was estimated 
by linear regression and the estimated regression coefficient is denoted as the beta value. The area of radiomic 
feature from the base line to the next time point was calculated using the formula for the area of a trapezoid. In 
this way, the area was calculated sequentially up to PD time point. AUC1 represents the sum of all calculated the 
areas. If the difference of radiomic feature’s values between the current time point and the next time point are 
positive, add it’s area value, otherwise subtract it’s area value. The total area was calculated by this method, which 
is denoted as AUC2. The correlations between AUC1, beta value, AUC2 and the six patterns obtained from the 
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longitudinal change of volume were calculated by Spearman’s rank correlation coefficient. The cut-off values that 
best predicted overall survival time based on AUC1, beta value, and AUC2 of volume were selected as the point 
with the most significant log-rank p-value for all possible cut-off points. Overall survival curves of AUC1, AUC2, 
and beta value based on cut-off values were estimated using the Kaplan-Meier method.
Prognostic prediction model using multivariate analysis. We calculated AUC2 for each of the 23 quantitative 
features. The cut-off values that best predicted overall survival time for the 23 baseline quantitative features and 
AUC2 of 23 quantitative features were selected. Univariate and multivariate analyses of the 23 baseline quantita-
tive features with age, sex, ECOG performance state, smoking status, type of EGFR mutation, and AUC2 of the 23 
quantitative features were performed using Cox’s proportional hazards model to identify risk factors associated 
with overall survival. Univariate analysis was used to select 18 features with a p value less than 0.05. Spearman’s 
correlation analysis of 18 features and longitudinal data represented by AUC2 was performed. Some features 
have a positive or negative correlation. We looked at the variance inflation factor (VIF) to see the collinearity 
between the features included in the multivariable cox regression. The VIF of all variables was less than and there 
was no collinearity. To identify significant features on Cox’s proportional hazard model, we considered stepwise 
selection with Akaike’s Information Criterion (AIC). For significant features of overall survival, a time-dependent 
receiver operating characteristic (ROC) curve was constructed, and the area under the ROC curve (AUROC) was 
calculated.
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